{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:38:44Z","timestamp":1760099924296,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.biopha.2006.11.005","type":"journal-article","created":{"date-parts":[[2006,12,30]],"date-time":"2006-12-30T07:07:18Z","timestamp":1167462438000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapy"],"prefix":"10.1016","volume":"61","author":[{"given":"Patrizia","family":"D'Eufemia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Tetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Celli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2006.11.005_bib1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S8756-3282(00)89007-9","article-title":"Osteogenesis Imperfecta","volume":"27","author":"Sillence","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2006.11.005_bib2","first-page":"1377","article-title":"Osteogenesis Imperfecta","volume":"365","author":"Glorieux","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2006.11.005_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","article-title":"Intravenous pamidronate treatment in children with moderate to severe Osteogenesis Imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first years of therapy","volume":"34","author":"Arikoski","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2006.11.005_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36months of age with Osteogenesis Imperfecta","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2006.11.005_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bone.2005.07.020","article-title":"The effect of cyclical intravenous pamidronate in children and adolescents with Osteogenesis Imperfecta type V","volume":"38","author":"Zeitlin","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.biopha.2006.11.005_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with Osteogenesis Imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.biopha.2006.11.005_bib7","first-page":"921","article-title":"Use of bisphosphonates in children and adolescent","volume":"15","author":"Allgrove","year":"2002","journal-title":"J Pediatr Endoscrinol Metab"},{"key":"10.1016\/j.biopha.2006.11.005_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates","volume":"264","author":"Van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopha.2006.11.005_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0928-0987(03)00108-8","article-title":"Inhibition of mevalonate pathway in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro","volume":"19","author":"Toyras","year":"2003","journal-title":"Eur J Pham Sci"},{"key":"10.1016\/j.biopha.2006.11.005_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanism of action","volume":"19","author":"Fleisch","year":"2000","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.biopha.2006.11.005_bib11","first-page":"55","article-title":"Short-term intravenous therapy with neridronate in Paget's disease","volume":"220","author":"Adami","year":"2002","journal-title":"Clin Exper Rheumatol"},{"key":"10.1016\/j.biopha.2006.11.005_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with Osteogenesis Imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.biopha.2006.11.005_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0753-3322(02)00287-1","article-title":"l-Arginine and l-Lysine stimulation on cultured human osteoblast","volume":"56","author":"Torricelli","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2006.11.005_bib14","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0024-3205(97)00297-X","article-title":"Distribution and disappearance of the radiolabeled carbon derived from l-arginine and taurine in the mouse","volume":"60","author":"Lubec","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.biopha.2006.11.005_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01345288","article-title":"Immunohistochemical localization of taurine in various tissue of the mouse","volume":"15","author":"Terauchi","year":"1998","journal-title":"Amino Acid"},{"key":"10.1016\/j.biopha.2006.11.005_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0003-9969(99)00067-9","article-title":"Inhibition of experimental bone resorption and osteoclast formation and survival by 2-aminoethanesulphonic acid","volume":"44","author":"Koide","year":"1999","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.biopha.2006.11.005_bib17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2174\/0929867054546582","article-title":"Taurine analogues; a new class of therapeutics: retrospect and prospect","volume":"1247","author":"Gupta","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.biopha.2006.11.005_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004770-200301000-00008","article-title":"The inhibitory effect of alendronate and taurine on osteoclast differentiation mediated by porphyromonas gengivalis sonicates in vitro","volume":"29","author":"Kum","year":"2003","journal-title":"J Endodon"},{"key":"10.1016\/j.biopha.2006.11.005_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in Osteogenesis Imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"10.1016\/j.biopha.2006.11.005_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/320769a0","article-title":"PITC derivatives in amino acid analysis","volume":"320","author":"Cohen","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2006.11.005_bib21","series-title":"Advances in nutritional research","first-page":"231","article-title":"The biology of taurine in nutrition and development","author":"Sturman","year":"1980"},{"key":"10.1016\/j.biopha.2006.11.005_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.1992.72.1.101","article-title":"Physiological action of taurine","volume":"72","author":"Huxtable","year":"1992","journal-title":"Physiol Rev"},{"key":"10.1016\/j.biopha.2006.11.005_bib23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0006-2952(01)00741-9","article-title":"Stimulation of ERK2 by taurine with enhanced alkaline phosphatase activity and collagen synthesis in osteoblast-like UMR-106 cells","volume":"62","author":"Park","year":"2001","journal-title":"Biochem Pharmac"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2006.11.005_bib24","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1007\/s00586-003-0622-z","article-title":"Bisphosphonates in osteoporosis","volume":"12","author":"Fleish","year":"2003","journal-title":"Eur Spine J"},{"key":"10.1016\/j.biopha.2006.11.005_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/adc.2003.036590","article-title":"Bisphosphonate treatment of bone disease","volume":"90","author":"Shaw","year":"2005","journal-title":"Arch Dis Child"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332206003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:37:59Z","timestamp":1760092679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332206003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0753332206003404"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2006.11.005","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2006.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}